The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 3, 2009, Pages 921-930

  Smith, Sean M ^a   Uslaner, Jason M ^a   Yao, Lihang ^a   Mullins, Chadwick M ^a   Surles, Nathan O ^a   Huszar, Sarah L ^a   McNaughton, Caitlyn H ^a   Pascarella, Danette M ^a   Kandebo, Monika ^a   Hinchliffe, Richard M ^a   Sparey, Tim ^b   Brandon, Nicholas J ^b   Jones, Brian ^c   Venkatraman, Shankar ^a   Young, Mary Beth ^a   Sachs, Nancy ^a   Jacobson, Marlene A ^a   Hutson, Peter H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Merck Sharp & Dohme Limited   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4H THIENO[3,2 B]PYRROLE 5 CARBOXYLIC ACID; AMPHETAMINE; DEXTRO AMINO ACID OXIDASE; DEXTRO AMINO ACID OXIDASE INHIBITOR; DEXTRO SERINE; DIZOCILPINE; DOPAMINE; ENZYME INHIBITOR; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CENTRAL NERVOUS SYSTEM; COGNITION; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RAT; RECOGNITION; SCHIZOPHRENIA;

AGED; ANIMALS; D-AMINO-ACID OXIDASE; DIZOCILPINE MALEATE; HABITUATION, PSYCHOPHYSIOLOGIC; HUMANS; MALE; MODELS, MOLECULAR; PYRROLES; RATS; RATS, WISTAR; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA; SERINE; THIOPHENES;

EID: 62449161854     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.147884     Document Type: Article

References (41)

1. Adage T, Trillat AC, Quattropani A, Perrin D, Cavarec L, Shaw J, Guerassimenko O. Giachetti C, Gréco B, Chumakov I, et al. (2008) In vitro and in vivo pharmacolog-ical profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur Neuropsychopharmacol 18:200-214.
2. Almond SL, Fradley RL, Armstrong EJ, Heavens RB, Rutter AR, Newman RJ, Chiu CS, Koimo R, Hutson PH, and Brandon NJ (2006) Behavioral and biochemical characterization of a mutant mouse strain lacking d-amino acid oxidase activity and its implications for schizophrenia. Mol Cell Neurosci 32:324-334.
3. Brandish PE, Chiu CS, Schneeweis J, Brandon NJ, Leech CL, Kornienko O, Scolnick EM. Strulovici B, and Zheng W (2006) A cell-based ultra-high-throughput screening assay for identifying inhibitors of d-amino acid oxidase. J Biomol Screen 11:481-487.
4. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, Bougueleret L, Barry C, Tanaka H, La Rosa P, et al. (2002) Genetic and physiological data implicating the new human gene G72 and the gene for d-ammo acid oxidase in schizophrenia. Proc Natl Acad Sci USA 99:13675-13680.
5. Cubelos B, Giménez C, and Zafra F (2005) Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb Cortex 15:448-459.
6. D'Aniello A, D'Onofrio G, Pischetola M, D'Anieilo G, Vetere A, Petrucelli L, and Fisher GH (1993) Biological role of d-amino acid oxidase and d-aspartate oxidase: effects of d-amino acids. J Biol Chem 268:26941-26949.
7. Depoortère R, Dargazanli G, Esteime-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M, Heaulme M, Santucci V, Decobert M, et al. (2005) Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharm.acology 30:1963-1985.
8. Hashimoto A (2002) Effect of the intracerebroventricular and systemic administration of l-serine on the concentrations of d-and l-serine in several brain areas and periphery of rat. Brain Res 955:214-220.
9. Hashimoto A, Nishikawa T, Konno R, Niwa A, Oka T, and Takahashi K (1993) Free d-serine, d-aspartate, and d-alanine in the central nervous system and serum in mutant mice lacking d-amino acid oxidase. Neurosci Lett 152:33-36.
10. Hashimoto A, Nishikawa T, Oka T, Takahashi K, and Hayashi T (1992) Determination of free amino acid enantiomers in rat brain and serum by high-performance liquid chromatography after derivatization with N-tert.-butyloxycarbonyl-l-cysteine and o-phthaldialdehyde. J Chromatogr 582:41-48.
11. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lmdström LH, and Iyo M (2005) Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 29:767-769.
12. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, et al. (2003) Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60:572-576.
13. Heresco-Levy U (2005) Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia. Expert Opin Emerg Drugs 10:827-844.
14. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, and Javitt DC (2002) Placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry 159:480-482.
15. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, and Kelly D (1996) Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610-617.
16. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, and Lichtenstem M (1999) Efficacy of high-dose glychie in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29-36.
17. Institute of Laboratory Animal Resources (1996) Guide for the Care and. Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
18. Javitt DC (1987) Negative schizophrenic symptomatology and the PCP (phencycli-dine) model of schizophrenia. Hillside J Clin Psychiatry 9:12-35.
19. Johnson JW and Ascher P (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325:529-531.
20. Kapur S and Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol-Biol Psychiatry 27:1081-1090.
21. Kemp JA and Leeson PD (1993) The glycine site of the NMDA receptor-five years on. Trends Pharmacol Sci 14:20-25.
22. Kinney GG, Sur C, Burno M, Mallorga PJ, Williams JB, Figueroa DJ, Wittmann M, Lemaire W, and Conn PJ (2003) The glychie transporter type 1 inhibitor N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl] sarcoshie potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci 23:7586-7591.
23. Konno R and Yasumura Y (1983) Mouse mutant deficient in d-ammo acid oxidase activity. Genetics 103:277-285.
24. Konno R and Yasumura Y (1992) d-Amino-acid oxidase and its physiological function. Int J Biochem 24:519-524.
25. Krug AW, Völker K, Dantzler WH, and Silbernagl S (2007) Why is d-serine nephrotoxic and alpha-aminoisobutyric acid protective? Am J Physiol Renal Physiol 293:F382-F390.
26. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Henhiger GR, Bowers MB Jr, and Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
27. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, and Tamminga CA (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25:455-467.
28. Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Perng CH, and Tsai GE (2008) Sarcoshie (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry 63:9-12.
29. Maekawa M, Watanabe M, Yamaguchi S, Konno R, and Hori Y (2005) Spatial learning and long-term potentiation of mutant mice lacking d-ammo-acid oxidase. Neurosci Res 53:34-38.
30. McBain GJ, Kleckner NW. Wyrick S, and Dingledine R (1989) Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Mol Pharmacol 36:556-565.
31. Moghaddam B (2003) Bringing order to the glutamate chaos in schizophrenia. Neuron 40:881-884.
32. Morikawa A, Hamase K, Inoue T, Konno R, Niwa A, and Zaitsu K (2001) Determination of free d-aspartic acid, d-serine and d-alanine in the brain of mutant mice lacking d-amino acid oxidase activity. J Chrom,atogr B Biomed Sci Appl 757:119-125.
33. Mothet JP, Parent AT, Wolosker H, Brady RO Jr, Linden DJ, Ferris CD, Rogawski MA, and Snyder SH (2000) d-Serine is an endogenous ligand for the glycine site of the N-methyl-d-aspartate receptor. Proc Natl Acad Sci USA 97:4926-4931.
34. Rutter AR, Fradley RL, Garrett EM, Chapman KL, Lawrence JM, Rosahl TW, and Patel S (2007) Evidence from gene knockout studies implicates Asc-1 as the primary transporter mediating d-serine reuptake in the mouse CNS. Eur J Neurosci 25:1757-1766.
35. Schumacher J, Jamra RA, Freudenberg J, Becker T, Ohlraun S, Otte AC, Tullius M, Kovalenko S, Bogaert AV, Maier W, et al. (2004) Examination of G72 and d-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol Psychiatry 9:203-207.
36. Smith KE, Borden LA, Hartig PR, Branchek T, and Weinshank RL (1992) Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 8:927-935.
37. Sparey T, Abeywickrema P, Almond S, Brandon N, Byrne N, Campbell A, Hutson PH, Jacobson M, Jones B, Munshi S, et al. (2008) The discovery of fused pyrrole carboxylic acids as novel, potent d-amino acid oxidase (DAO) inhibitors. Bioorg Med Chem Lett 18:3386-3391.
38. Tsai G, Lane HY, Yang P, Chong MY, and Lange N (2004) Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 55:452-456.
39. Tsai GE, Yang P, Chang YC, and Chong MY (2006) d-Alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 59:230-234.
40. Tsai G, Yang P, Chung LC, Lange N, and Coyle JT (1998) d-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081-1089.
41. Verrall L, Walker M, Rawlings N, Benzel I, Kew JN, Harrison PJ, and Burnet PW (2007) d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. Eur J Neurosci 26:1657-1669.